227 related articles for article (PubMed ID: 33442693)
1. MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease.
Liu R; Americo JL; Cotter CA; Earl PL; Erez N; Peng C; Moss B
bioRxiv; 2021 Jan; ():. PubMed ID: 33442693
[TBL] [Abstract][Full Text] [Related]
2. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.
Liu R; Americo JL; Cotter CA; Earl PL; Erez N; Peng C; Moss B
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33688035
[TBL] [Abstract][Full Text] [Related]
3. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
J Virol; 2024 Jun; ():e0052124. PubMed ID: 38874361
[TBL] [Abstract][Full Text] [Related]
4. Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice.
Cotter CA; Americo JL; Earl PL; Moss B
NPJ Vaccines; 2023 Mar; 8(1):47. PubMed ID: 36973267
[TBL] [Abstract][Full Text] [Related]
5. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
García-Arriaza J; Garaigorta U; Pérez P; Lázaro-Frías A; Zamora C; Gastaminza P; Del Fresno C; Casasnovas JM; Sorzano CÓS; Sancho D; Esteban M
J Virol; 2021 Mar; 95(7):. PubMed ID: 33414159
[TBL] [Abstract][Full Text] [Related]
7. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
8. Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV).
Zheng Q; Chen D; Li P; Bi Z; Cao R; Zhou B; Chen P
Virus Genes; 2007 Dec; 35(3):585-95. PubMed ID: 17922181
[TBL] [Abstract][Full Text] [Related]
9. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.
Pérez P; Albericio G; Astorgano D; Flores S; Sánchez-Corzo C; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2023; 14():1264323. PubMed ID: 38155964
[TBL] [Abstract][Full Text] [Related]
10. MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge.
Meseda CA; Stauft CB; Selvaraj P; Lien CZ; Pedro C; Nuñez IA; Woerner AM; Wang TT; Weir JP
NPJ Vaccines; 2021 Dec; 6(1):145. PubMed ID: 34862398
[TBL] [Abstract][Full Text] [Related]
11. Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages.
Neckermann P; Mohr M; Billmeier M; Karlas A; Boilesen DR; Thirion C; Holst PJ; Jordan I; Sandig V; Asbach B; Wagner R
Front Immunol; 2024; 15():1338492. PubMed ID: 38380318
[TBL] [Abstract][Full Text] [Related]
12. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2021; 12():824728. PubMed ID: 35154086
[TBL] [Abstract][Full Text] [Related]
13. Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses.
Chavan R; Marfatia KA; An IC; Garber DA; Feinberg MB
J Virol; 2006 Aug; 80(15):7676-87. PubMed ID: 16840346
[TBL] [Abstract][Full Text] [Related]
14. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
Bisht H; Roberts A; Vogel L; Bukreyev A; Collins PL; Murphy BR; Subbarao K; Moss B
Proc Natl Acad Sci U S A; 2004 Apr; 101(17):6641-6. PubMed ID: 15096611
[TBL] [Abstract][Full Text] [Related]
15. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
[TBL] [Abstract][Full Text] [Related]
16. Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
Gómez-Carballa A; Albericio G; Montoto-Louzao J; Pérez P; Astorgano D; Rivero-Calle I; Martinón-Torres F; Esteban M; Salas A; García-Arriaza J
Antiviral Res; 2023 Dec; 220():105760. PubMed ID: 37992765
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.
Grandpre LE; Duke-Cohan JS; Ewald BA; Devoy C; Barouch DH; Letvin NL; Reinherz EL; Baden LR; Dolin R; Seaman MS
Vaccine; 2009 Mar; 27(10):1549-56. PubMed ID: 19168105
[TBL] [Abstract][Full Text] [Related]
18. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
Front Immunol; 2021; 12():772240. PubMed ID: 34858430
[TBL] [Abstract][Full Text] [Related]
19. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.
López-Gil E; Lorenzo G; Hevia E; Borrego B; Eiden M; Groschup M; Gilbert SC; Brun A
PLoS Negl Trop Dis; 2013; 7(7):e2309. PubMed ID: 23875044
[TBL] [Abstract][Full Text] [Related]
20. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
